New drug cocktail targets Hard-to-Treat bladder cancer
NCT ID NCT07241793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing a drug called trastuzumab rezetecan, either alone or with an immunotherapy drug called adebrelimab, in people with advanced bladder cancer that has a protein called HER2. The study aims to see if these treatments can shrink tumors or slow the cancer's growth. It is recruiting 96 adults whose cancer has spread or cannot be removed by surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab rezetecan (a targeted cancer drug) and adebrelimab (an immunotherapy drug)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced bladder cancer that has HER2 protein, potentially shrinking tumors or slowing disease progression.
- What could go wrong
- This is an early phase II trial with only 96 participants, so results may not apply to everyone. The drugs can cause side effects like infusion reactions or immune-related issues, and the combination may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangxi Cancer Center
RECRUITINGNanchang, Jiangxi, 330000, China
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510000, China
-
Sun yat-sen university cancer center
RECRUITINGGuangzhou, Guangdong, 510000, China
-
The Second Affiliated Hospital of Kunming Medical University
NOT_YET_RECRUITINGKunming, Yunnan, 650033, China
-
The fifth Affiliated Hospital of Guangzhou Medcial University
RECRUITINGGuangzhou, Guangdong, 510000, China
-
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers